SCHEMBL3012916

SCHEMBL3012916

O=S(=O)(c1ccc(Br)cc1)N1CCN(c2nc(Cc3ccc(F)c(F)c3)cs2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.49
ALDH1A1 P00352 3/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
USP2 O75604 2/20 0.43
HSD17B10 Q99714 2/20 0.43
MAPT P10636 1/20 0.43
RECQL P46063 1/20 0.43
GAA P10253 2/20 0.40
GPR183 P32249 2/20 0.40
LMNA P02545 1/20 0.39
KDM4E B2RXH2 2/20 0.39
NAMPT P43490 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
GBA1 P04062 2/20 0.38
HPGD P15428 1/20 0.38
PKM P14618 2/20 0.38
TSHR P16473 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3016148 0.92 SMN1; SMN2 (0.48) SMN1; SMN2ALDH1A1L3MBTL1USP2HSD17B10
SCHEMBL3019261 0.92 SMN1; SMN2 (0.48) SMN1; SMN2ALDH1A1L3MBTL1USP2HSD17B10
SCHEMBL3012883 0.92 ALDH1A1 (0.49) SMN1; SMN2ALDH1A1L3MBTL1USP2HSD17B10
SCHEMBL3017331 0.92 ALDH1A1 (0.59) SMN1; SMN2ALDH1A1L3MBTL1USP2HSD17B10
SCHEMBL3119908 0.91 SMN1; SMN2 (0.50) SMN1; SMN2ALDH1A1L3MBTL1USP2HSD17B10
SCHEMBL3010528 0.90 ALDH1A1 (0.49) SMN1; SMN2ALDH1A1L3MBTL1USP2HSD17B10
SCHEMBL3010726 0.90 MEN1 (0.43) SMN1; SMN2ALDH1A1L3MBTL1USP2HSD17B10
SCHEMBL3015337 0.88 ALDH1A1 (0.47) SMN1; SMN2ALDH1A1L3MBTL1USP2HSD17B10
SCHEMBL3007387 0.88 ALDH1A1 (0.53) SMN1; SMN2ALDH1A1L3MBTL1USP2HSD17B10
SCHEMBL3649352 0.88 ALDH1A1 (0.48) SMN1; SMN2ALDH1A1L3MBTL1USP2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885ALDH1A1 3510/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.